Naomi Sato

Naomi Sato

Auto-generated profile, based on publicly available information

Naomi Sato

Department of Pathology Tohoku Medical and Pharmaceutical University Hospital Sendai Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2022 in New Biotechnology
Verified
Journal Article
Open access
XLXuan Chinh Luu
Xuan Chinh Luu
YSYosuke Shida
Yosuke Shida
YSYoshiyuki Suzuki
Yoshiyuki Suzuki
NSNaomi Sato
Naomi Sato
ANAkihiro Nakumura
Akihiro Nakumura
WOWataru Ogasawara
Wataru Ogasawara
Droplet-based microfluidic technology is a powerful tool for single-cell cultivation and rapid isolation of bacteria, yeasts and algae. However, it has been of limited use for studies of filamentous fungi due to the fast growth of their branched hyphae. The long regeneration time for fungal protoplasts and low-throughput screening methods are inherent problems for current genetic transformation techniques. Therefore, we have developed a novel droplet-based method for the filamentous fungus Trichoderma reesei expressing green fluorescent protein (GFP) as a marker. This approach presented several outstanding advantages over the traditional transformation method, including a 7-fold reduction in time for T. reesei protoplast regeneration, an 8-fold increase in regeneration frequency, and a screening speed of up to 8,000 droplets min-1. In this study, we encapsulated and incubated the gfp-transformed T. reesei protoplasts in droplets for 24 h, screened the droplets in a high-throughput assay, and eventually collected a transformant library with over 96 % of the candidates transformed with the marker gene. This versatile approach should make fungi more amenable to genetic manipulation and encourage strain improvements for industrial applications.

1 October 2018 in Human Pathology
Verified
Journal Article
Closed access
NSNaomi Sato
Naomi Sato
FFFumiyoshi Fujishima
Fumiyoshi Fujishima
YNYasuhiro Nakamura
Yasuhiro Nakamura
YAYayoi Aoyama
Yayoi Aoyama
YOYoshiaki Onodera
Yoshiaki Onodera
HSHironobu Sasano
Hironobu Sasano

1 June 2010 in Psychiatric Genetics
Verified
Journal Article
Closed access
NSNaomi Sato
Naomi Sato
SKShinji Kageyama
Shinji Kageyama
RCRenyin Chen
Renyin Chen
MSMasaya Suzuki
Masaya Suzuki
FTFumihiko Tanioka
Fumihiko Tanioka
Haruhiko SugimuraHaruhiko Sugimura
Haruhiko Sugimura

1 January 2022
Verified
Conference Paper
Open access
PDF file
NSNaomi Sato
Naomi Sato
MIMasaru Isonuma
Masaru Isonuma
KAKimitaka Asatani
Kimitaka Asatani
SIShoya Ishizuka
Shoya Ishizuka
ASAori Shimizu
Aori Shimizu
ISIchiro Sakata
Ichiro Sakata
Naomi Sato, Masaru Isonuma, Kimitaka Asatani, Shoya Ishizuka, Aori Shimizu, Ichiro Sakata. Findings of the Association for Computational Linguistics: EMNLP 2022. 2022.


7 August 2026 in IJU Case Reports
Verified
Journal Article
Open access
YSYuki Seki
Yuki Seki
KMKento Morozumi
Kento Morozumi
NSNaomi Sato
Naomi Sato
MOMasaaki Oikawa
Masaaki Oikawa
HKHiroki Kusumoto
Hiroki Kusumoto
YKYasuhiro Kaiho
Yasuhiro Kaiho
Introduction: Accessory adrenal oncocytomas are rare. Consequently, the clinical characteristics and management of this entity remain poorly defined. Case Presentation: A 65‐year‐old man presented with a retroperitoneal mass. Imaging revealed a 103 × 96 mm tumor adjacent to the left kidney. Hormonal evaluation indicated the tumor was nonfunctioning; however, dehydroepiandrosterone sulfate and neuron‐specific enolase levels were elevated, and malignancy could not be excluded. The tumor was resected laparoscopically. Histopathological examination revealed oncocytic features, and immunohistochemistry demonstrated positivity for steroidogenic factor 1. The tumor was anatomically separate from the normal adrenal gland, supporting the diagnosis of an accessory adrenal oncocytoma. Based on the Lin–Weiss–Bisceglia criteria, the tumor was classified as borderline malignant potential. No recurrence has been observed during 2 years of follow‐up. Conclusion: Accessory adrenal oncocytomas are rare entities, and their accurate diagnosis requires a comprehensive, integrated approach incorporating clinical findings, imaging studies, and detailed pathological evaluation.